Skip to main content

Abeona Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Developments

Abeona’s first-ever U.S. Biologics License Application (BLA) submission completed in September 2023

FDA decision on priority review and acceptance of BLA for pz-cel (prademagene zamikeracel, formerly known as EB-101) in recessive dystrophic epidermolysis bullosa (RDEB) expected by late-November 2023

Initiated commercial readiness activities for potential U.S. launch of pz-cel

CLEVELAND, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today reported financial results for the third quarter of 2023 and provided corporate updates.

“In the third quarter, we made substantial progress in our evolution from a late-stage clinical development company to one with significant commercial opportunity,” said Vish Seshadri, Chief Executive Officer of Abeona. “With the completion of Abeona’s first-ever U.S. BLA submission, we moved a step closer toward the potential approval of pz-cel as the first therapy that delivered instantaneous wound coverage and multi-year healing in RDEB wounds with a one-time application in clinical trials. In addition, we are also establishing Abeona’s capabilities in late-stage development and manufacturing of autologous engineered cell therapies. Lastly, we have initiated commercial readiness activities for our potential launch of pz-cel.”

Third Quarter and Recent Progress

Pz-cel for RDEB

  • The proposed non-proprietary (generic) name prademagene zamikeracel (referred to as “pz-cel” going forward) was approved by the World Health Organization as the International Nonproprietary Name for Abeona’s investigational autologous, COL7A1 gene-corrected epidermal sheets formerly known as EB-101.
  • In August, Abeona completed a positive pre-BLA meeting in which it reached alignment with the U.S. Food and Drug Administration (FDA) that the pz-cel clinical efficacy and safety data appear adequate to support a BLA submission. The FDA also agreed that retroviral vector manufactured at Abeona and Indiana University appear comparable based on the data that Abeona provided in its briefing book.
  • In September, Abeona submitted a BLA to FDA seeking approval with priority review of pz-cel for RDEB. The FDA’s decision on BLA acceptance is typically made during the 60-day window following submission. If accepted with Priority Review, Abeona expects potential BLA approval in the second quarter of 2024.

Strengthened balance sheet, initiated U.S. commercial launch preparations for pz-cel

  • Abeona raised $25 million in a registered direct offering priced at-the-market with select existing institutional investors to primarily fund the Company’s initial commercial preparations in support of the potential U.S. launch of pz-cel.
  • Appointed Madhav Vasanthavada, Ph.D., M.B.A. as Chief Commercial Officer and Head of Business Development. Dr. Vasanthavada brings over 20 years of diverse leadership experience in the life sciences industry with recent experience in launching autologous cell therapies at Bristol Myers Squibb (BMS) and Celgene.
  • Started U.S. commercial launch planning activities for pz-cel, including initiating onboarding discussions with EB treatment sites, payer engagement, and hiring key commercial roles.

Third Quarter Financial Results

Cash, cash equivalents, restricted cash and short-term investments totaled $54.1 million as of September 30, 2023, including the net proceeds from the $25 million registered direct offering in July 2023, as compared to $37.1 million as of June 30, 2023. Abeona estimates that its cash and cash equivalents, restricted cash and short-term investments as of September 30, 2023 are sufficient resources to fund operations into the fourth quarter of 2024.

Research and development expenses for the three months ended September 30, 2023 were $7.1 million, compared to $5.5 million for the same period of 2022. General and administrative expenses were $4.2 million for the three months ended September 30, 2023, compared to $3.9 million for the same period of 2022. Net loss attributable to common shareholders was $11.8 million for the third quarter of 2023, or $0.48 loss per common share as compared to a net loss attributable to common shareholders of $6.4 million, or $1.00 loss per common share, in the third quarter of 2022.

Conference Call Details

Abeona Therapeutics will host a conference call and webcast today, November 13, 2023, at 8:30 a.m. ET, to discuss its financial results and developments. To access the call, dial 888-506-0062 (U.S. toll-free) or 973-528-0011 (international) and Entry Code: 963663 five minutes prior to the start of the call. A live, listen-only webcast and archived replay of the call can be accessed on the Investors & Media section of Abeona’s website at The archived webcast replay will be available for 30 days following the call.

About Abeona Therapeutics
Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing cell and gene therapies for serious diseases. Abeona’s lead clinical program is pz-cel (prademagene zamikeracel, formerly known as EB-101), its investigational autologous, COL7A1 gene-corrected epidermal sheets currently in development for recessive dystrophic epidermolysis bullosa. The Company’s development portfolio also features AAV-based gene therapies for ophthalmic diseases with high unmet medical need. Abeona’s novel, next-generation AAV capsids are being evaluated to improve tropism profiles for a variety of devastating diseases. Abeona’s fully integrated cell and gene therapy cGMP manufacturing facility produced pz-cel for the pivotal Phase 3 VIITAL™ study and is capable of clinical and potential commercial production of AAV-based gene therapies. For more information, visit

Forward-Looking Statements
This press release contains certain statements that are forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and that involve risks and uncertainties. We have attempted to identify forward-looking statements by such terminology as “may,” “will,” “believe,” “anticipate,” “expect,” “intend,” “potential,” and similar words and expressions (as well as other words or expressions referencing future events, conditions or circumstances), which constitute and are intended to identify forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, numerous risks and uncertainties, including but not limited to, the timing and outcome of our Biologics License Application submission to the FDA for pz-cel; continued interest in our rare disease portfolio; our ability to enroll patients in clinical trials; the outcome of future meetings with the FDA or other regulatory agencies, including those relating to preclinical programs; the ability to achieve or obtain necessary regulatory approvals; the impact of any changes in the financial markets and global economic conditions; risks associated with data analysis and reporting; and other risks disclosed in the Company’s most recent Annual Report on Form 10-K and subsequent periodic reports filed with the Securities and Exchange Commission. The Company undertakes no obligation to revise the forward-looking statements or to update them to reflect events or circumstances occurring after the date of this press release, whether as a result of new information, future developments or otherwise, except as required by the federal securities laws.

Condensed Consolidated Statements of Operations and Comprehensive Loss
(In thousands, except share and per share amounts)

  For the three months ended September 30, For the nine months ended September 30,
   2023   2022   2023   2022 
License and other revenues $  $  $3,500  $1,346 
Royalties  30      1,605   350 
Research and development  7,148   5,490   23,712   22,693 
General and administrative  4,156   3,890   13,174   11,574 
Impairment of licensed technology           1,355 
Loss/(gain) on right-of-use lease assets        (1,065)  1,561 
Impairment of construction-in-progress           1,792 
Total expenses  11,334   9,380   37,426   39,325 
Loss from operations  (11,334)  (9,380)  (33,926)  (37,979)
Interest income  593   72   1,374   110 
Interest expense  (105)  (157)  (309)  (558)
Change in fair value of warrant liabilities  (1,101)  3,050   (7,465)  5,995 
Other income (expense)  111   (19)  2,729   (143)
Net loss $(11,836) $(6,434) $(37,597) $(32,575)
Deemed dividends related to Series A and Series B Convertible Redeemable Preferred Stock           (3,782)
Net loss attributable to Common Shareholders $(11,836) $(6,434) $(37,597) $(36,357)
Basic and diluted loss per common share $(0.48) $(1.00) $(1.89) $(6.05)
Weighted average number of common        
shares outstanding – basic and diluted  24,797,564   6,421,245   19,942,613   6,009,902 
Other comprehensive income (loss):        
Change in unrealized gains (losses) related to available-for-sale debt securities (33)  (4)  1   (11)
Foreign currency translation adjustments  29   (6)  29   (6)
Comprehensive loss $                 (11,840) $                    (6,444) $                  (37,567) $                  (36,374)


Condensed Consolidated Balance Sheets
(In thousands, except share and per share amounts)

 September 30, 2023 December 31, 2022
Current assets:   
Cash and cash equivalents$4,712  $14,217 
Short-term investments 49,042   37,932 
Restricted cash 338   338 
Other receivables 2,209   188 
Prepaid expenses and other current assets 963   424 
        Total current assets 57,264   53,099 
Property and equipment, net 3,999   5,741 
Right-of-use lease assets 4,685   5,331 
Other assets 139   43 
        Total assets$66,087  $64,214 
Current liabilities:   
Accounts payable$2,592  $1,811 
Accrued expenses 3,972   3,991 
Current portion of lease liability 1,649   1,773 
Other current liabilities 199   204 
        Total current liabilities 8,412   7,779 
Payable to licensor 4,472   4,163 
Long-term lease liabilities 4,043   5,854 
Warrant liabilities 27,122   19,657 
        Total liabilities 44,049   37,453 
Commitments and contingencies   
Stockholders' equity:   
Preferred stock - $0.01 par value; authorized 2,000,000 shares; No shares issued and outstanding as of September 30, 2023 and December 31, 2022, respectively     
Common stock - $0.01 par value; authorized 200,000,000 shares; 24,713,908 and 17,719,720 shares issued and outstanding as of September 30, 2023 and December 31, 2022, respectively 247   177 
Additional paid-in capital 754,823   722,049 
Accumulated deficit (732,933)  (695,336)
Accumulated other comprehensive loss (99)  (129)
        Total stockholders' equity 22,038   26,761 
        Total liabilities and stockholders' equity$66,087  $64,214 

Investor and Media Contact:
Greg Gin
VP, Investor Relations and Corporate Communications
Abeona Therapeutics

Primary Logo

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.